-+ 0.00%
-+ 0.00%
-+ 0.00%

Bonesupport Holding (OM:BONEX) Stock Faces Rich Valuation As 16.6% Margin Reshapes Narratives

Simply Wall St·07/17/2026 19:21:42
语音播报

Bonesupport Holding (OM:BONEX) has opened Q2 2026 with Total Revenue of SEK355.7 million and Net Income of SEK81.9 million, setting up a results season where investors are focused on how this earnings run rate backs up the recent move in the share price around SEK199.9. The company has reported quarterly revenue of SEK283.5 million in Q1 2025 and SEK355.7 million in Q2 2026, while quarterly Net Income was SEK10.4 million and SEK81.9 million over the same period. Trailing twelve month Net Income is SEK213.9 million, putting the spotlight on how durable these margins look.

See our full analysis for Bonesupport Holding.

With the latest numbers on the table, the next step is to set them against the most widely held narratives around Bonesupport Holding and see which views the new margin profile supports and which it starts to challenge.

See what the community is saying about Bonesupport Holding

OM:BONEX Revenue & Expenses Breakdown as at Jul 2026
OM:BONEX Revenue & Expenses Breakdown as at Jul 2026

Margins Backed By 16.6% Trailing Profit

  • On a trailing twelve month basis, Bonesupport Holding earned SEK213.9 million of Net Income on SEK1,286.4 million of Total Revenue, which lines up with the reported 16.6% net margin and gives you a sense of how much profit the business is currently keeping from its sales.
  • Supporters of the bullish view point to this margin profile as a foundation for future upside, yet their assumptions can be demanding:
    • Consensus narrative materials refer to profit margins rising from around the current mid teens level to roughly 30% in a few years, so the present 16.6% margin still leaves a sizeable gap for that thesis to be met.
    • The bullish narrative also talks about higher margin mix from wider use of CERAMENT G and potential CERAMENT V approval, and investors can now compare those expectations directly with the current SEK213.9 million of trailing earnings to judge how much improvement is already reflected in the story.

Revenue Run Rate Near SEK1.3b Tests Growth Narratives

  • Trailing twelve month revenue sits at SEK1,286.4 million versus quarterly revenue of SEK355.7 million in Q2 2026 and SEK324.0 million in Q1 2026, so the recent quarters show Bonesupport Holding operating at a revenue pace that is consistent with the last year as a whole.
  • Consensus narrative materials highlight expected revenue growth of about 22.4% per year from here, which investors can weigh against the current run rate:
    • Bulls argue that wider use of CERAMENT products and new indications could support higher growth than the 22.4% figure, yet the present SEK1,286.4 million base means any acceleration needs to build on a much larger revenue pool than a few years ago.
    • Bears focus on early stage adoption in new geographies and segments, and the fact that revenue is already near SEK1.3b gives them a concrete benchmark to question how quickly additional centers and procedures will move the needle from this starting point.

Bulls arguing that CERAMENT adoption can materially lift growth from a SEK1,286.4 million revenue base may want to see how that story plays out across the full bullish narrative 🐂 Bonesupport Holding Bull Case

High P/E And DCF Fair Value Create Valuation Tension

  • The stock currently trades at SEK199.9 with a trailing P/E of 61.5x, compared with an analyst price target in the supplied data of SEK360.83 and a DCF fair value of SEK480.36, so the valuation data shows a clear gap between market price, analyst targets and modelled cash flow value.
  • Skeptics highlight this valuation gap from a different angle, arguing that high expectations are already built in:
    • The cautious narrative notes that even the more conservative analysts still assume earnings grow from around SEK151.9 million in the recent period to over SEK700 million by 2029, implying several times today’s profit, which some bears view as a stretch when compared with the current SEK213.9 million trailing Net Income.
    • At the same time, the P/E of 61.5x is far above the 16.2x industry average cited in the analysis data, so critics argue that any slowdown from the recent 44.6% earnings growth rate versus the longer term 50.7% figure could leave the stock exposed if the market decides this premium is too rich.

If you are weighing whether the current 61.5x P/E and SEK199.9 price fairly reflect those more cautious earnings paths, it can help to see how the full bearish narrative frames that risk 🐻 Bonesupport Holding Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Bonesupport Holding on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and cautious views on Bonesupport Holding feels finely balanced, this is the moment to look at the numbers yourself and decide where you stand. To see what is driving optimism around the stock, start by reviewing its 4 key rewards

Explore Alternatives Beyond Bonesupport Holding

Bonesupport Holding currently carries a P/E of 61.5x against a cited 16.2x industry average and relies on ambitious earnings projections, which leaves the valuation exposed if expectations soften.

If that kind of rich pricing backed by demanding forecasts makes you cautious, it is worth spending a few minutes with 224 high quality undervalued stocks to hunt for stocks where pricing looks more conservative and expectations leave more room for error.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.